The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...
The FDA has approved Pfizer’s marstacimab (Hympavzi ... under FDA review is Sanofi’s fitusiran. This siRNA-based drug knocks down levels of the anticoagulant antithrombin, potentially ...
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...
As October draws to a close, it's time to take a look at the regulatory news that made headlines in the month and look ahead to ...
This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
On Tuesday, the FDA approved ... For Pfizer and GSK, RSV vaccines are critical as they seek to build new revenue streams before facing generic competition for their top-selling drugs.
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance(1) ...
Shares of Sangamo Therapeutics surged 69% after the genetic medicines developer announced regulatory progress in its quest to ...
Cash runway is not expected to get Intellia to meaningful data readouts for their Phase III trials. See why NTLA stock is a ...